SanofiNASDAQ: SNY

French drugmaker Sanofi is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin brand Lantus, newspaper Handelsblatt reported on Monday.

French drugmaker Sanofi is nearing a decision to invest between 1.3 billion and 1.5 billion euros ($1.4-$1.6 billion) to upgrade its production of long-acting insulin shots in Germany, a person familiar with the plan told Reuters on Monday.

VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK. Verona has the potential for further growth beyond the current approval, although in the near-term, initial sales seem likely to be a major determinant of the stock's direction.

Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.

- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company's small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies - - Company expects proceeds to extend cash runway into 2026 - WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, is pleased to announce that Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock.

AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi.

Availability of the Q2 2024 Aide-mémoire Paris, France – June 25, 2024. Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q2-results-2024 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.

ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi's commitment to bring potential first- and best-in-class treatments to the rare blood disorders community Interim results from the long-term XTEND-ed phase 3 study demonstrate once-weekly ALTUVIIIO continues to provide highly effective bleed protection New ATLAS phase 3 study data reinforce the potential of fitusiran to provide prophylaxis for people with hemophilia A or B, with or without inhibitors New Drug Application for fitusiran accepted for review by the US Food and Drug Administration, with a PDUFA date of March 28, 2025 Paris, June 21, 2024. Sanofi will present new data from its hemophilia portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place June 22-26, 2024, in Bangkok, Thailand.

Belharra today announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases.